Form 4: Guardant Health Executive AmirAli Talasaz Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Co-Chief Executive Officer AmirAli Talasaz reports the acquisition of restricted stock units in Guardant Health, Inc.
Summary
- AmirAli Talasaz, Co-Chief Executive Officer of Guardant Health, Inc., filed a Form 4 indicating changes in beneficial ownership.
- The report details the acquisition of 19,258 restricted stock units (RSUs) on March 12, 2025, vesting in equal quarterly installments.
- Additionally, 116,010 restricted stock units were acquired on the same date, vesting 33% on January 1, 2026, and the remaining 67% in equal quarterly installments over the subsequent two years.
- Following these transactions, Talasaz directly owns 135,268 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating an executive's acquisition of restricted stock units, which is generally a positive sign of alignment with company goals but doesn't inherently indicate strong positive or negative sentiment.
Positives
- The acquisition of restricted stock units by a high-ranking executive can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules of the RSUs suggest a multi-year commitment from the executive.
Industry Context
This filing is a routine disclosure related to executive compensation and equity ownership, common in the biotechnology and healthcare industries.
Comparison to Industry Standards
- Executive compensation packages including restricted stock units are standard practice in publicly traded companies, particularly in high-growth sectors like biotechnology.
- Companies like Illumina, Inc. and Exact Sciences Corp also use RSUs as part of their executive compensation packages to align management interests with shareholder value.
Stakeholder Impact
- The acquisition of RSUs by a top executive could positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of transaction: Acquisition of restricted stock units. |
| 03/13/2025 | Date of signature for the Form 4 filing. |
| 03/31/2025 | First vesting date for 19,258 RSUs. |
| 06/30/2025 | Second vesting date for 19,258 RSUs. |
| 09/30/2025 | Third vesting date for 19,258 RSUs. |
| 12/31/2025 | Fourth vesting date for 19,258 RSUs. |
| 01/01/2026 | First vesting date for 33% of 116,010 RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.